208 related articles for article (PubMed ID: 10929699)
1. Miglitol and hepatotoxicity in type 2 diabetes mellitus.
Carlson RF
Am Fam Physician; 2000 Jul; 62(2):315, 318. PubMed ID: 10929699
[No Abstract] [Full Text] [Related]
2. [Reducing postprandial glucose levels. Glucosidase antagonists].
Neye H
Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
[No Abstract] [Full Text] [Related]
3. Miglitol for type 2 diabetes mellitus.
Med Lett Drugs Ther; 1999 May; 41(1053):49-50. PubMed ID: 10368700
[No Abstract] [Full Text] [Related]
4. [Alpha-glucosidase inhibitor for type 2 diabetic patients. Clinical study with miglitol].
Fehmann HC
MMW Fortschr Med; 2000 May; 142(21):55. PubMed ID: 10872296
[No Abstract] [Full Text] [Related]
5. alpha-Glucosidase inhibition in the treatment of diabetes mellitus.
Dimitriadis G; Raptis S
Horm Metab Res Suppl; 1992; 26():42-9. PubMed ID: 1490691
[No Abstract] [Full Text] [Related]
6. [Drug therapy of type 2 diabetes: insulin sensitizers improve results].
Stadler HJ
Pflege Z; 1999 Nov; 52(11):772-5. PubMed ID: 10788929
[No Abstract] [Full Text] [Related]
7. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
[TBL] [Abstract][Full Text] [Related]
8. Acarbose, an alpha-glucosidase inhibitor for non-insulin-dependent diabetes.
Welborn TA
Med J Aust; 1998 Jan; 168(2):76-8. PubMed ID: 9469188
[No Abstract] [Full Text] [Related]
9. Type 2 diabetes: glycemic targets and oral therapies for older patients.
Lardinois CK
Geriatrics; 1998 Nov; 53(11):22-3, 27-8, 33-4 passim. PubMed ID: 9824974
[TBL] [Abstract][Full Text] [Related]
10. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
11. [Inhibitors of alpha-glucosidase].
Toeller M
Journ Annu Diabetol Hotel Dieu; 1991; ():203-12. PubMed ID: 1886331
[No Abstract] [Full Text] [Related]
12. [Risk of complications in the diabetic patient. Postprandial blood glucose peaks as deciding factor].
MMW Fortschr Med; 2000 Jul; 142(26-27):54-5. PubMed ID: 10929491
[No Abstract] [Full Text] [Related]
13. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
Scott LJ; Spencer CM
Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
[TBL] [Abstract][Full Text] [Related]
14. Improving management of type 2 diabetes mellitus: 1. alpha-Glucosidase inhibitors.
Kuritzky L; Samraj G; Quillen DM
Hosp Pract (1995); 1999 Sep; 34(10):43-6. PubMed ID: 10901748
[No Abstract] [Full Text] [Related]
15. [Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Kellerer M; Jakob S; Linn T; Haslbeck M
MMW Fortschr Med; 2003 Dec; 145(51-52):I-X; quiz XI-XII. PubMed ID: 14974337
[No Abstract] [Full Text] [Related]
16. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus.
Mitrakou A; Tountas N; Raptis AE; Bauer RJ; Schulz H; Raptis SA
Diabet Med; 1998 Aug; 15(8):657-60. PubMed ID: 9702468
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Scheen AJ
Drugs; 2003; 63(10):933-51. PubMed ID: 12699398
[TBL] [Abstract][Full Text] [Related]
19. Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus.
Sels JP; Kingma PJ; Wolffenbuttel BH; Menheere PP; Branolte JH; Nieuwenhuijzen Kruseman AC
Neth J Med; 1994 Jun; 44(6):198-201. PubMed ID: 8052342
[TBL] [Abstract][Full Text] [Related]
20. Potential pharmacokinetics interference between alpha-glucosidase inhibitors and other oral antidiabetic agents.
Scheen AJ; Lefèbvre PJ
Diabetes Care; 2002 Jan; 25(1):247-8. PubMed ID: 11772929
[No Abstract] [Full Text] [Related]
[Next] [New Search]